NOD-like receptors in autoimmune diseases. 2021

Li Chen, and Shi-Qi Cao, and Ze-Min Lin, and Shi-Jun He, and Jian-Ping Zuo
Laboratory of Immunopharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.

Autoimmune diseases are chronic immune diseases characterized by dysregulation of immune system, which ultimately results in a disruption in self-antigen tolerance. Cumulative data show that nucleotide-binding and oligomerization domain (NOD)-like receptors (NLRs) play essential roles in various autoimmune diseases, such as inflammatory bowel disease (IBD), rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), psoriasis, multiple sclerosis (MS), etc. NLR proteins, consisting of a C-terminal leucine-rich repeat (LRR), a central nucleotide-binding domain, and an N-terminal effector domain, form a group of pattern recognition receptors (PRRs) that mediate the immune response by specifically recognizing cellular pathogen-associated molecular patterns (PAMPs) or damage-associated molecular patterns (DAMPs) and triggering numerous signaling pathways, including RIP2 kinase, caspase-1, nuclear factor kappa B (NF-κB), mitogen-activated protein kinase (MAPK) and so on. Based on their N-terminal domain, NLRs are divided into five subfamilies: NLRA, NLRB, NLRC, NLRP, and NLRX1. In this review, we briefly describe the structures and signaling pathways of NLRs, summarize the recent progress on NLR signaling in the occurrence and development of autoimmune diseases, as well as highlight numerous natural products and synthetic compounds targeting NLRs for the treatment of autoimmune diseases.

UI MeSH Term Description Entries
D007192 Indenes A family of fused-ring hydrocarbons isolated from coal tar that act as intermediates in various chemical reactions and are used in the production of coumarone-indene resins.
D011725 Pyridines Compounds with a six membered aromatic ring containing NITROGEN. The saturated version is PIPERIDINES.
D005663 Furans Compounds with a 5-membered ring of four carbons and an oxygen. They are aromatic heterocycles. The reduced form is tetrahydrofuran. Tetrahydrofurans
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000070576 NLR Proteins Intracellular signaling proteins that are defined by the presence of a NUCLEOTIDE-binding region and LEUCINE-rich repeats. Their general structure consists of any of a variety of effector domains at their N-termini such as a caspase recruitment domain (CARD), a central nucleotide-binding domain, and a variable number of C-terminal leucine-rich repeats. They are important for pathogen recognition in the INNATE IMMUNE RESPONSE of animals and plants. Members of the NLR protein family include the NOD SIGNALING ADAPTOR PROTEINS. NOD-like Receptor,Nucleotide-Binding Domain Leucine-Rich Repeat Protein,NLR Protein,NOD-like Receptors,Nucleotide-binding Domain Leucine-rich Repeat Proteins,NOD like Receptor,NOD like Receptors,Nucleotide Binding Domain Leucine Rich Repeat Protein,Nucleotide binding Domain Leucine rich Repeat Proteins,Protein, NLR,Proteins, NLR,Receptor, NOD-like,Receptors, NOD-like
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001327 Autoimmune Diseases Disorders that are characterized by the production of antibodies that react with host tissues or immune effector cells that are autoreactive to endogenous peptides. Autoimmune Disease,Disease, Autoimmune,Diseases, Autoimmune
D013449 Sulfonamides A group of compounds that contain the structure SO2NH2. Sulfonamide,Sulfonamide Mixture,Sulfonamide Mixtures,Mixture, Sulfonamide,Mixtures, Sulfonamide

Related Publications

Li Chen, and Shi-Qi Cao, and Ze-Min Lin, and Shi-Jun He, and Jian-Ping Zuo
November 2013, Frontiers in immunology,
Li Chen, and Shi-Qi Cao, and Ze-Min Lin, and Shi-Jun He, and Jian-Ping Zuo
January 2009, Arthritis research & therapy,
Li Chen, and Shi-Qi Cao, and Ze-Min Lin, and Shi-Jun He, and Jian-Ping Zuo
April 2007, Microbes and infection,
Li Chen, and Shi-Qi Cao, and Ze-Min Lin, and Shi-Jun He, and Jian-Ping Zuo
January 2016, Yonsei medical journal,
Li Chen, and Shi-Qi Cao, and Ze-Min Lin, and Shi-Jun He, and Jian-Ping Zuo
October 2013, Frontiers in immunology,
Li Chen, and Shi-Qi Cao, and Ze-Min Lin, and Shi-Jun He, and Jian-Ping Zuo
November 2022, Acta pharmacologica Sinica,
Li Chen, and Shi-Qi Cao, and Ze-Min Lin, and Shi-Jun He, and Jian-Ping Zuo
January 2007, Annals of medicine,
Li Chen, and Shi-Qi Cao, and Ze-Min Lin, and Shi-Jun He, and Jian-Ping Zuo
January 2018, International journal of physiology, pathophysiology and pharmacology,
Li Chen, and Shi-Qi Cao, and Ze-Min Lin, and Shi-Jun He, and Jian-Ping Zuo
January 2022, Frontiers in immunology,
Li Chen, and Shi-Qi Cao, and Ze-Min Lin, and Shi-Jun He, and Jian-Ping Zuo
December 2015, Current opinion in immunology,
Copied contents to your clipboard!